SCHEMBL4375887

SCHEMBL4375887

Cc1cc(C(=O)O)ccc1-n1c(C)cc(O)cc1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 5/20 0.65
ESR1 P03372 1/20 0.65
ALOX15 P16050 1/20 0.65
PTPN7 P35236 1/20 0.65
HSD17B10 Q99714 1/20 0.65
ALDH1A1 P00352 4/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
POLB P06746 3/20 0.47
APEX1 P27695 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
NPSR1 Q6W5P4 2/20 0.42
RECQL P46063 1/20 0.42
PTPN1 P18031 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.40
HTR7 P34969 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12798353 0.88 ALDH1A1 (0.57) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL4387429 0.85 ALDH1A1 (0.47) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL2115309 0.79 MYC (1.00) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL4374369 0.79 NPSR1 (0.42) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL4377764 0.79 ALDH1A1 (0.52) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL4384693 0.75 NR4A1 (0.59) MYCALOX15PTPN7HSD17B10ALDH1A1
SCHEMBL2706645 0.73 ALDH1A1 (0.60) ALOX15HSD17B10ALDH1A1L3MBTL1MEN1
SCHEMBL12798350 0.73 MAPK14 (0.48) ALDH1A1L3MBTL1MAPTPOLBAPEX1
SCHEMBL13610554 0.73 HSP90AB1 (0.47) MYCESR1ALOX15PTPN7HSD17B10
SCHEMBL6649551 0.73 MYC (0.54) MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MYC 4291/4885ESR1 3659/4885ALOX15 2346/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MYC 4410/4885ESR1 2703/4885ALOX15 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.